The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
August 29th 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.
New Acute Migraine Co-Primary End Points Provide Positives for Trial Design
April 22nd 2019A review of newly implemented primary end points—pain freedom and most bothersome symptom freedom at 2 hours—used in 8 clinical trials may help to guide future migraine researchers in the design of acute treatment trials.
Erenumab Efficacious In Episodic Migraine Patients With Prior Treatment Failure
April 16th 2019The study also added to a growing base of findings which suggest that patients who have failed preventive medications prior to trial participation have lower placebo responses, which could have implications for clinical trial design.
Migraine Days Reduced Long-Term After Galcanezumab Treatment Cessation
April 15th 2019Data from the EVOLVE-1 and EVOLVE-2 phase 3 clinical trials suggest that galcanezumab (Emgality, Eli Lilly) can maintain ≥50% responder rates equivalent to that of placebo while reducing more monthly migraine days for 5 months after halting treatment.
Guidelines for Pediatric Migraine Clinical Trial Design Released
April 8th 2019The International Headache Society has issued a number of recommendations for the proper design of trials for the prevention of pediatric migraine, hoping to address the challenges which are unique to pediatric patient populations.
Improving Pediatric Headache Care Through Better Performance on Headache Quality Measures
March 28th 2019Implementing evidence-based practices consistent with the AAN Headache Quality Measures has the potential to improve the quality of care in this patient population, however, additional study is required to determine if better process performance produces better outcomes.
Head of NCI Ned Sharpless Named Acting FDA Commissioner
March 13th 2019Ned Sharpless, MD, the director of the National Cancer Institute, has been named to the position of acting FDA Commissioner. The announcement was made just a week after the current commissioner, Scott Gottlieb, MD, announced his plans to resign in early April.